CROSS-STANDARD public interest · Home/clinical medical device

China-to-Canada Medical Device Compliance Gap Matrix

AI-compiled from official public sources — cross-checked by multiple AI models, not human-verified. Informational only; see disclaimer. Public-interest, source-linked comparison of common China home and clinical medical device documentation against Canadian Medical Devices Regulations SOR/98-282 requirements: device classification (MDL/MDEL), MDSAP-certified ISO 13485 QMS, electromedical safety (CAN/CSA-C22.2 No. 60601-1 / IEC 62304), clinical and safety-effectiveness evidence, Regulatory Correspondent and MDEL, and bilingual (English + French) labelling with Canadian UDI.

Dataset 2026-06-11 Last verified 2026-06-12 6 rows

GAP MATRIX

Compliance Gap Matrix

Gap matrix
Compliance item Common China baseline Canada (Health Canada / MDSAP) Gap / action Source + verification date
Device Classification — Health Canada Classes I–IV and MDL/MDEL China NMPA classifies medical devices into Class I (lowest risk, filing only), Class II (moderate risk, provincial NMPA registration), and Class III (highest risk, national NMPA registration) under the Administrative Measures for the Registration and Filing of Medical Devices (2021, NMPA Order No. 47). Classification follows the NMPA Classification Catalogue (医疗器械分类目录). Active electromedical devices typically fall in Class II or III. Importers of foreign devices must obtain an NMPA import registration certificate; there is no separate importer-establishment licence requirement analogous to MDEL.医疗器械注册与备案管理办法 (2021, NMPA Order No. 47)
医疗器械分类目录 (2017, NMPA Announcement No. 104; amended by subsequent announcements — verify current edition)
医疗器械监督管理条例 (2021, State Council Order No. 739)		 Canada's Medical Devices Regulations SOR/98-282 (under the Food and Drugs Act) classify medical devices into four classes (I–IV) based on the potential risk they pose. Class I carries the lowest risk and requires no pre-market licence; Class II, III, and IV require a Medical Device Licence (MDL) issued by Health Canada's Medical Devices Directorate before sale in Canada. Classification rules are set out in Schedule 1 of SOR/98-282. Electromedical (active) devices intended for diagnosis or treatment typically fall in Class II–IV depending on clinical use and invasiveness. The importer or distributor of a foreign-manufactured device also needs a Medical Device Establishment Licence (MDEL) under Section 44–48 of SOR/98-282.Medical Devices Regulations SOR/98-282, Schedule 1 (Classification Rules)
Medical Devices Regulations SOR/98-282, Sections 26–32 (MDL requirements for Class II–IV)
Medical Devices Regulations SOR/98-282, Sections 44–48 (MDEL requirements)
Food and Drugs Act RSC 1985 c F-27, Section 26		 Canada's four-class system (I–IV) and China's three-class system use different criteria and risk logic; the same device may receive different risk classes under each. NMPA classification cannot be mapped directly to Health Canada classification — an independent classification determination under SOR/98-282 Schedule 1 is required. A Class II NMPA device may be Class III or IV in Canada, triggering significantly more demanding MDL requirements. Additionally, Canada imposes a separate MDEL obligation on importers and distributors — a structural requirement absent from the NMPA framework. Chinese manufacturers must plan for both an MDL (product) and an MDEL (establishment) for their Canadian importer.[INFORMATIONAL ONLY] A Chinese manufacturer entering the Canadian market must independently classify the device under SOR/98-282 Schedule 1 — NMPA class is not transferable. Class II–IV requires a Health Canada MDL before sale; the Canadian importer/distributor must hold an MDEL. Both licences must be in place before any commercial supply. Classification errors are a primary market-access blocker. Consult a qualified Canadian regulatory affairs professional for device-specific classification advice. Government of Canada — Justice Laws (Medical Devices Regulations SOR/98-282)2026-06-12 · unverified
Clinical and Safety-Effectiveness Evidence for MDL (Class II–IV) NMPA requires clinical evaluation for all Class II and Class III device registrations under the 2021 Administrative Measures (Order No. 47). Clinical evaluation may take the form of: (a) clinical trial conducted in China (GCP-compliant, in NMPA-registered clinical trial institutions); (b) clinical literature evaluation (data from published studies on equivalent devices); or (c) exemption from clinical trials for devices in the NMPA Exempt Catalogue. Class III devices require more comprehensive clinical evidence; novel devices typically require a clinical trial. Risk management per YY/T 0316 is required. Preclinical data (biocompatibility per GB/T 16886 series, animal testing where applicable) is included in the registration technical dossier.医疗器械注册与备案管理办法 (2021, NMPA Order No. 47), Articles 16–22
医疗器械临床评价技术指导原则 (NMPA 2021 clinical evaluation guidance)
YY/T 0316-2016 — Risk management (aligned to ISO 14971:2007)
GB/T 16886 series — Biological evaluation of medical devices
医疗器械临床试验质量管理规范 (GCP for Medical Devices, NMPA/NHC 2016)		 Section 32 of the Medical Devices Regulations SOR/98-282 requires that a Class II, III, or IV MDL application include objective evidence demonstrating that the device is safe and effective for its intended purpose. For Class II, a declaration of conformity to applicable standards (with supporting evidence) may suffice for many devices, but Health Canada may request additional safety and effectiveness data. For Class III and IV devices, comprehensive safety-effectiveness data is mandatory — this typically includes clinical data (clinical investigations, published clinical literature, post-market clinical data, or a clinical evaluation report), preclinical data (bench testing, animal studies where applicable), and risk management documentation per ISO 14971:2019. For novel devices (no predicate), a full clinical investigation may be required. Health Canada's pre-market review guidance specifies the evidence standard for each class.Medical Devices Regulations SOR/98-282, Section 32 (information required in a licence application)
Medical Devices Regulations SOR/98-282, Sections 11–17 (safety and effectiveness requirements)
Health Canada Guidance: Safety and Effectiveness Requirements for Medical Devices — hc-sc.gc.ca
ISO 14971:2019 — Application of risk management to medical devices
Health Canada Guidance: Conducting Clinical Investigations of Medical Devices in Canada		 Both Canada and China require clinical and safety-effectiveness evidence, but the standards and formats differ. Key gaps: (1) Health Canada expects clinical data in internationally recognised formats (ICH E2 or equivalent structure for clinical evidence summaries); NMPA-formatted clinical reports may need restructuring for Health Canada review; (2) Health Canada Class III/IV may require a clinical evaluation report explicitly referencing applicable IMDRF or Health Canada guidance on clinical evidence sufficiency — this is not automatically satisfied by an NMPA clinical dossier; (3) Risk management must use ISO 14971:2019; CN YY/T 0316 is aligned to the 2007 version — the 2019 version has substantive changes (notably dropping the ALARP framing) that may require dossier updates; (4) Clinical investigations conducted only in China (Chinese population, Chinese sites) may face Health Canada questions on generalisability to the Canadian population for certain device types; (5) Preclinical biocompatibility data to GB/T 16886 is substantially aligned to ISO 10993 series and generally portable, but specific test method deviations should be identified.[INFORMATIONAL ONLY] Chinese manufacturers with a completed NMPA clinical dossier have a substantive evidence base, but must review and reformat clinical evidence summaries to align with Health Canada guidance and IMDRF clinical evaluation frameworks. Risk management documentation should be updated to ISO 14971:2019. Biocompatibility data to GB/T 16886 is generally portable to ISO 10993 — verify specific test method alignment. Consult a qualified Canadian regulatory affairs professional for class-specific evidence requirements before submitting an MDL application. Health Canada — Safety and Effectiveness Requirements for Medical Devices2026-06-12 · unverified
Importer / Distributor Establishment Licence (MDEL) — Documented Procedures under SOR/98-282 s.45 China requires foreign manufacturers to appoint a domestic agent (境内代理人) who is registered in China, acts as the co-applicant for the NMPA product registration, and is the Chinese regulatory contact. The domestic agent is jointly responsible with the manufacturer for the registration application and ongoing post-market obligations under Chinese law. There is no direct MDEL equivalent for importers under the NMPA framework — import permits and registration certificates are product-specific, not establishment-based in the same way. Chinese distributors and importers are subject to the Medical Device Distribution Quality Management Practices (医疗器械经营质量管理规范) under NMPA Order No. 54 (2022), which requires documented procedures but is less prescriptive than MDEL s.45 in scope.医疗器械监督管理条例 (2021, State Council Order No. 739), Article 40 (domestic agent requirement)
医疗器械注册与备案管理办法 (2021, NMPA Order No. 47)
医疗器械经营质量管理规范 (2022, NMPA Order No. 54) — distribution quality management practices		 Under the Medical Devices Regulations SOR/98-282, any person who imports or distributes a Class II, III, or IV medical device into Canada for sale must hold a Medical Device Establishment Licence (MDEL) issued by Health Canada (ss.44–48). The MDEL is an establishment-level licence — it is granted to the Canadian importer or distributor, not to the product. To obtain and maintain an MDEL, the establishment must have documented procedures covering: distribution records, complaint handling, recalls, mandatory problem reporting, handling/storage/delivery/installation, corrective action, and servicing (s.45). There is no requirement in s.45 for an ISO 13485 certificate or a certified quality management system — the obligation is documented procedures plus an annual review to verify the procedures remain current and effective. The foreign manufacturer (Class II–IV) applies separately for a Medical Device Licence (MDL) under ss.26–32; the MDL application requires quality system evidence (an MDSAP audit report per s.32(1)(c)). Label fields required by ss.21–23 identify the manufacturer, device name, and other product-level particulars — there is no regulatory requirement in SOR/98-282 for a 'Regulatory Correspondent' name or address to appear on the label.Medical Devices Regulations SOR/98-282, Sections 44–48 (MDEL requirements)
Medical Devices Regulations SOR/98-282, Section 45 (documented procedures for MDEL holders)
Medical Devices Regulations SOR/98-282, Sections 26–32 (MDL requirements for manufacturers)
Medical Devices Regulations SOR/98-282, Sections 21–23 (label requirements)
Health Canada Guidance: Medical Device Establishment Licence (MDEL) — hc-sc.gc.ca		 The Canadian MDEL is structurally distinct from the Chinese domestic agent model: (1) The MDEL is an establishment licence granted to the Canadian importer/distributor — China has no equivalent importer-level establishment licence requiring documented s.45 procedures; (2) The MDEL requires documented procedures for distribution records, complaints, recalls, mandatory problem reporting, handling/storage/delivery/installation, corrective action, and servicing, plus annual review — Chinese NMPA Order No. 54 procedures are comparable in intent but differ in scope and specifics; (3) The MDEL must be obtained by the importer before any commercial importation of Class II–IV devices; failure to hold an MDEL is an offence under the Food and Drugs Act; (4) ISO 13485 certification is NOT required for the MDEL — it is required for the manufacturer's MDL (via MDSAP); (5) The foreign manufacturer's MDL application requires a Canadian regulatory contact for Health Canada correspondence, but this is a MDL application administrative requirement, not a mandatory label field under ss.21–23.[INFORMATIONAL ONLY] A Canadian importer or distributor of Class II–IV medical devices must obtain an MDEL from Health Canada before any commercial importation. The MDEL requires documented procedures covering the activities listed in s.45, plus annual review — it does not require ISO 13485 certification. The foreign manufacturer must separately apply for an MDL, which requires MDSAP audit evidence of ISO 13485 compliance (s.32). Both licences must be in place before commercial sale in Canada. This is not legal or regulatory advice; consult a qualified Canadian regulatory affairs professional. Government of Canada — Medical Devices Regulations SOR/98-282 (Justice Laws)2026-06-13 · unverified
Labelling — Mandatory Bilingual (English and French), UDI, and Regulatory Correspondent China's labelling requirements for medical devices are set out in the Medical Device Instructions for Use (IFU) and Labelling Management Measures (国家药监局令第6号, 2021). Labels must be in Chinese; foreign languages may be added alongside but cannot replace Chinese. Mandatory elements include: product name; model/specification; intended use; manufacturer name and address; manufacturing date and validity period; batch/lot number; registration certificate number; and warnings/precautions. NMPA UDI system (effective from 2021, phased by class) requires a UDI carrier on the label with DI and PI from NMPA-recognised issuing agencies. NMPA UDI codes are not transferable to the Canadian HCUDI system — a separate Canadian UDI from a Health Canada-recognised agency must be obtained.医疗器械说明书和标签管理规定 (NMPA Order No. 6, 2021)
NMPA UDI Regulations (NMPA Order No. 19, 2019; phased implementation from 2021)
国家药监局关于发布医疗器械唯一标识系统规则的公告 (2019 No. 10)		 Sections 21–25 of the Medical Devices Regulations SOR/98-282 set out labelling requirements for devices sold in Canada. All mandatory label information must appear in both English and French (Canada's two official languages under the Official Languages Act RSC 1985 c 31). Mandatory label elements for Class II–IV devices include: device name and intended use; manufacturer name and address; Regulatory Correspondent (Canadian Agent) name and address; device class; licence number (once MDL is granted); lot or batch number; manufacturing and expiry date (where applicable); instructions for use (IFU) or reference to them; sterility indicators (where applicable); any warnings, precautions, or contraindications. Unique Device Identification (UDI): Health Canada's UDI regulations (SOR/2021-101, in force 2024–2026 phase-in by class) require Class II–IV devices to carry a UDI on the label — a Device Identifier (DI) and Production Identifier (PI) in both human-readable (HRI) and Automatic Identification and Data Capture (AIDC) format. UDI data must be submitted to Health Canada's UDI Database (HCUDI). UDI issuing agencies recognised by Health Canada include GS1, HIBCC, and ICCBBA.Medical Devices Regulations SOR/98-282, Sections 21–25 (labelling requirements)
Medical Devices Regulations SOR/98-282, Part 1.1 (UDI requirements, added by SOR/2021-101)
Official Languages Act RSC 1985 c 31 (English and French bilingual requirement)
Health Canada UDI Regulations SOR/2021-101 — Unique Device Identification of Medical Devices Regulations
Health Canada Guidance: Labelling of Medical Devices — hc-sc.gc.ca		 The bilingual (English + French) requirement is Canada-specific and has no Chinese equivalent — all Chinese device labels are Chinese-only, so a complete Canadian label redesign is required. Key gaps: (1) Mandatory bilingual text for all label elements — English alone is not sufficient in Canada; French translations of device name, intended use, IFU, warnings, and all mandatory elements must be on the label or in the package insert; (2) Regulatory Correspondent (Canadian Agent) name and address must appear on the label — not required on Chinese labels; (3) MDL licence number must appear on the label once granted — NMPA registration number format differs; (4) Canadian UDI (from GS1, HIBCC, or ICCBBA) in both HRI and AIDC format on the label, with data submitted to HCUDI — NMPA UDI codes are not accepted; UDI phase-in for Class II devices was 2024; Class III/IV were earlier (verify current status of phase-in on hc-sc.gc.ca); (5) IFU must be bilingual in English and French for the Canadian market.[INFORMATIONAL ONLY] Chinese medical device labels are Chinese-only and will require complete redesign for the Canadian market. All mandatory label elements must appear in both English and French; the Regulatory Correspondent's Canadian address must be on the label; and a Canadian UDI (from GS1, HIBCC, or ICCBBA) in both HRI and AIDC format must be applied, with data submitted to Health Canada's HCUDI database. IFU must also be bilingual. NMPA UDI codes are not accepted in Canada. Budget sufficient time (typically 3–6 months) for bilingual translation, Canadian UDI assignment, label redesign, and HCUDI registration before Canadian market launch. This is informational; seek qualified Canadian regulatory and translation services. Health Canada — Guidance Document: Labelling of Medical Devices2026-06-12 · unverified
Quality Management System — MDSAP-certified ISO 13485 (mandatory for Class II–IV in Canada) China requires compliance with the NMPA Medical Device Good Manufacturing Practice (医疗器械生产质量管理规范, GMP) for all licensed manufacturers. Many Chinese manufacturers additionally hold ISO 13485 certification, which is required for NMPA Class II and III registration. However, Chinese ISO 13485 certification is issued by domestic CNAS-accredited or CNCA-authorised certification bodies — these are not MDSAP-accredited Auditing Organizations and their audit reports are not accepted by Health Canada as MDSAP evidence. NMPA GMP audits are conducted by NMPA/provincial bureaus; they do not cover the multi-jurisdictional scope of MDSAP.医疗器械生产质量管理规范 (NMPA GMP) — Order No. 64 (2014); superseded by NMPA Order No. 107 (issued Nov 2025, effective Nov 2026)
ISO 13485:2016 / YY/T 0287-2017 (widely adopted by CN exporters)
医疗器械监督管理条例 (2021, State Council Order No. 739)		 Since 1 January 2019, Health Canada accepts only MDSAP (Medical Device Single Audit Program) audit reports as evidence of compliance with the ISO 13485:2016 QMS requirements for Class II, III, and IV device licence applications. MDSAP is a single audit programme conducted by MDSAP-accredited Auditing Organizations (AOs) that covers five regulatory authorities: Health Canada, US FDA, ANVISA (Brazil), TGA (Australia), and PMDA (Japan). The MDSAP audit replaces Health Canada's own Quality System audits for licensing purposes. Manufacturers must hold a current, favourable MDSAP audit report (Grade 1 or 2; Grade 5 triggers immediate Health Canada review). The QMS must conform to ISO 13485:2016 and address all applicable MDSAP regulatory requirements across the five jurisdictions covered. The MDSAP audit cycle is typically three years with annual surveillance audits.Medical Devices Regulations SOR/98-282, Section 32(1)(c) (QMS evidence required for MDL)
Health Canada Guidance: Medical Device Single Audit Program (MDSAP) — hc-sc.gc.ca
ISO 13485:2016 — Medical devices — Quality management systems — Requirements for regulatory purposes
MDSAP AU P0002.003 — MDSAP Audit Approach (IMDRF document)		 This is the most operationally significant gap for Chinese manufacturers targeting Canada. China's ISO 13485 certification (even from an internationally recognised certification body) is not equivalent to an MDSAP audit report for Health Canada MDL purposes — MDSAP must be conducted by an IMDRF-recognised MDSAP Auditing Organization. A Chinese manufacturer must: (1) engage an MDSAP-accredited AO (list published on the IMDRF website); (2) undergo a full MDSAP initial audit covering all five regulatory authority requirements; (3) obtain a Grade 1 or 2 audit report. The MDSAP initial audit typically takes 6–18 months from engagement depending on AO availability and manufacturer readiness. Ongoing 3-year cycle with annual surveillance audits is required for licence maintenance. ISO 13485 foundation is necessary but not sufficient — the MDSAP overlay adds regulatory-authority-specific checklists for all five jurisdictions.[INFORMATIONAL ONLY] A Chinese manufacturer holding ISO 13485 certification has the quality management foundation for MDSAP, but must engage an IMDRF-recognised MDSAP Auditing Organization to conduct a full MDSAP audit before applying for a Canadian Class II–IV MDL. NMPA GMP audits and domestic ISO 13485 certificates are not accepted substitutes. Plan for 6–18 months for the initial audit process plus annual surveillance audits thereafter. This is not legal or regulatory advice; consult a qualified Canadian regulatory affairs professional and an MDSAP Auditing Organization. Health Canada — Medical Devices Directorate2026-06-12 · unverified
Electromedical Safety — CAN/CSA-C22.2 No. 60601-1 / IEC 60601-1 and IEC 62304 GB 9706.1-2020 is China's mandatory national standard for general requirements for basic safety and essential performance of medical electrical equipment, aligned to IEC 60601-1 Ed.3 with minor Chinese deviations — mandatory for new NMPA registrations from 2023-05-01. YY 9706.102-2021 covers EMC (aligned to IEC 60601-1-2 Ed.4). For software, YY/T 0664-2020 (aligned to IEC 62304) covers software lifecycle processes. Risk management is addressed by YY/T 0316-2016 (aligned to ISO 14971:2007). Testing must be by CNAS-accredited or NMPA-designated laboratories. Because GB 9706.1-2020 and CAN/CSA-C22.2 No. 60601-1:14 both derive from IEC 60601-1 Ed.3, significant test data overlap exists; however, separate Canadian-compliant test reports are required for MDL submission.GB 9706.1-2020 — Medical electrical equipment — Part 1: General requirements for basic safety and essential performance (aligned to IEC 60601-1 Ed.3, mandatory from 2023-05-01)
YY 9706.102-2021 — EMC standard for medical electrical equipment (aligned to IEC 60601-1-2 Ed.4, mandatory from 2023-07-01)
YY/T 0664-2020 — Medical device software lifecycle processes (aligned to IEC 62304)
YY/T 0316-2016 — Risk management (aligned to ISO 14971:2007)		 Health Canada does not maintain a harmonised standards list in the EU sense; instead, manufacturers are expected to meet applicable recognised standards as part of the MDL technical dossier. For electromedical equipment, the primary recognised standard is CAN/CSA-C22.2 No. 60601-1:14 (the Canadian adoption of IEC 60601-1 Ed.3.1 with Canadian deviations). This covers general requirements for basic safety and essential performance of medical electrical equipment. Applicable particular standards (CAN/CSA 60601-2-x series or IEC 60601-2-x) must additionally be applied for specific device types. For devices incorporating software, IEC 62304:2006+AMD1:2015 (medical device software lifecycle processes) is the recognised standard for software safety classification and lifecycle documentation, referenced in Health Canada guidance and required in the MDL technical dossier for software-containing devices. Risk management per ISO 14971:2019 is expected for all Class II–IV device technical dossiers. Test reports must come from accredited laboratories (SCC-accredited or recognised ISO 17025 laboratory).CAN/CSA-C22.2 No. 60601-1:14 — Medical electrical equipment — Part 1: General requirements for basic safety and essential performance (Canadian adoption of IEC 60601-1 Ed.3.1)
IEC 60601-2-x particular standards series (device-type specific)
IEC 62304:2006+AMD1:2015 — Medical device software — Software life cycle processes
ISO 14971:2019 — Medical devices — Application of risk management to medical devices
Medical Devices Regulations SOR/98-282, Section 32 (technical documentation for MDL)
Health Canada Guidance Document: Guidance on the Risk-Based Classification System for Non-In-Vitro Diagnostic Devices		 Both CAN/CSA-C22.2 No. 60601-1:14 and GB 9706.1-2020 derive from IEC 60601-1 Ed.3, so core physical safety test parameters (leakage current, dielectric withstand, insulation, mechanical strength) substantially overlap — test data portability is high. Key gaps: (1) Health Canada requires test reports citing CAN/CSA-C22.2 No. 60601-1:14 (including Canadian deviations) from an SCC-accredited or ISO 17025-recognised laboratory; GB 9706.1-2020 reports alone do not satisfy this; (2) For software-containing devices, IEC 62304-based documentation (software safety classification A/B/C, software development lifecycle records) is required for MDL — YY/T 0664-2020 is aligned but CN documentation may need reformatting for Health Canada review format; (3) Risk management must reference ISO 14971:2019 (CN equivalent YY/T 0316 is aligned to the older 2007 version — verify currency); (4) No formal harmonised-standard presumption mechanism exists in Canada as in the EU, but use of recognised standards creates a strong compliance presumption in the MDL dossier.[INFORMATIONAL ONLY] A device already tested to GB 9706.1-2020 (IEC 60601-1 Ed.3 aligned) has strong test-data overlap with CAN/CSA-C22.2 No. 60601-1:14 requirements, reducing re-testing burden for Canada. However, Health Canada MDL submission requires test reports explicitly citing CAN/CSA-C22.2 No. 60601-1:14, issued by an SCC-accredited laboratory. For software-containing devices, IEC 62304-aligned documentation and ISO 14971:2019 risk management records must be prepared for the technical dossier. Engage a Canadian regulatory affairs professional and an SCC-accredited test laboratory early in the export planning process. This is informational only. Health Canada — Guidance Document: Licensing of Medical Devices2026-06-12 · unverified

E-E-A-T

Named editorial review

Pending named reviewer

Official regulator, standards body, notified body, customs, or primary legal source preferred. Local PDFs are not accepted.

Editorial controls

Rows must include publisher, official URL, access date, verification flag, and last_verified before human_reviewed can be true.

SOURCES

Official-source register.